Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Extrachromosomal Circular DNA and Transposable Elements in Type 2 Diabetes

Moya-Valera C., Arita AF., Lara-Hernández F., García-García AB., Chaves FJ.

Narrative Review on Type 2 Diabetes, published in Int J Mol Sci (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Int J Mol Sci (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41373670
PMCID
PMC12692015
DOI
10.3390/ijms262311516

Abstract (original English)

Type 2 Diabetes (T2D) is a complex disease that arises from interaction between genetic and environmental factors. The activation of transposable elements (TEs) and the production of circular extrachromosomal DNA (eccDNA) may represent genetic mechanisms involved in cellular aging, metabolic alterations, and T2D development through distinct pathways. Although the origin and characteristics of TEs and eccDNA differ substantially, eccDNA can in some cases be derived from TEs. This review summarizes the current understanding of these mechanisms and examines the reported associations between T2D and either TEs or eccDNAs. These findings highlight the significant involvement of these molecules in disease pathogenesis, particularly in relation to aging, and underscore their great potential as biomarkers and targets for T2D prevention.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansDiabetes Mellitus, Type 2DNA, CircularDNA Transposable Elements

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research